* REVEAL-CKD data show alarming prevalence of undiagnosed Stage 3 chronic kidney disease across France, Germany, Italy, Japan and US

* Findings from INSIDE-CKD demonstrate that Farxiga could cut 33 percent of healthcare costs by delaying disease progression and reducing incidence of cardiorenal events

AstraZeneca, a leader in cardiorenal research, presented new data at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, US on the importance of earlier screening and diagnosis of chronic kidney disease (CKD) and the impact of Farxiga on reducing healthcare costs1,2. These findings were also simultaneously published in the Journal of the American Society of Nephrology.

CKD affects 850 million people worldwide with increasing prevalence3, yet the vast majority of patients go undiagnosed4. Data from the REVEAL-CKD multinational study found high rates of underdiagnosis, 61.6% to 95.5%, in the countries studied (US, Italy, Germany, Japan and France). Country-specific electronic medical records and insurance claims were analysed for patients with estimated glomerular filtration rate (eGFR) between >=30 and

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE